Benzinga
Benzinga
Benzinga
giovedì, settembre 24

Mineralys Therapeutics Inc

MLYSNASDAQ
Trade with Public
Trade with Public
$26.89
-2.51-8.54%
In chiusura: Sep 22, 5:00 PM EST
$27.41
-1.99-6.77%
Pre-mercato: 5:44 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Mineralys Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mineralys Therapeutics (MLYS).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$49Upside to Avg. PT+77.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Apr 27, 2026TD CowenTara BancroftInitiateBuy—
Mar 13, 2026B of A SecuritiesGreg HarrisonPT RaiseBuy$46→$51
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved